(DTIL) – Globe Newswire
-
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of
-
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Cand
-
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Cand
-
Precision BioSciences Announces CEO Transition Plan
-
Precision BioSciences Announces CEO Transition Plan
-
Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day
-
Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
-
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
-
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
-
Precision BioSciences to Present at Upcoming Virtual Investor Conferences
-
Precision BioSciences to Present at Upcoming Virtual Investor Conferences
-
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates
-
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates
-
Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
-
Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
-
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
-
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
-
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
-
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
-
Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company
-
Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company
-
Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference
-
Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference
-
Precision BioSciences Announces Executive Leadership Change
-
Precision BioSciences Announces Executive Leadership Change
-
Elo Life Systems Publishes the Most Detailed Genome Map in the Industry to Improve Quality and Supply Chain Stability of Vanilla
-
Elo Life Systems Publishes the Most Detailed Genome Map in the Industry to Improve Quality and Supply Chain Stability of Vanilla
-
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
-
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
-
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
-
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
-
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
-
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
-
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
-
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
-
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
-
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
-
Elo Life Systems Appoints Food and Beverage Industry Technology Leader Alec Hayes as Vice President of Technology and Products
-
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
-
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
-
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
-
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
-
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
-
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
Back to DTIL Stock Lookup